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Background: The immunomodulatory drug leflunomide (LEF) is frequently used for treating human
cytomegalovirus (HCMV), but its antiviral mechanism is still unclear. In this study,we therefore investigated the
effects of the active LEF metabolite A771726 on the HCMV lifecycle in human embryonic lung fibroblasts. We
clarified the mechanism of LEF antiviral infection, and provide a new way to treat immune dysfunction patients
with HCMV infection.
Methods: The experiment was divided into four groups: the control group, the HCMV group, the ganciclovir +
HCMV group as well as the LEF + HCMV group. MTT was usedfor assessment of the cell inhibitory rate. Apoptosis
was measured by staining with fluorescein isothiocyanate Annexin V and propidium iodide. Statistical significance
was determined by paired t-test using SPSS software.
Results: The results of the study showed that cell proliferation was significantly inhibited by HCMV at 24 hours and
48 hours. With increasing HCMV concentration, the value-added inhibition of the cells was significantly decreased
compared with the control group, and was statistically significant (P <0.01). Ganciclovir can increase proliferation of
cellsinfected with HCMV; compared with the control group it was statistically significant (P <0.05). Meanwhile, with
LEF treatment cell proliferation was significantly improved at 24 hours and 48 hours, with statistical significance
(P <0.05). The apoptosis rate of human embryonic lung fibroblasts infected with HCMV increased significantly at
24 hours, 48 hours and 72 hours, and as time goes on the apoptosis rate increases statistically significantly (P <0.01)
compared with the control group The apoptosis rate of theHCMV infection group decreased by adding LEF,and
was statistically significant (P <0.05).
Conclusions: In this studywe show that LEF is an exciting new drug for cytomegalovirus infection. LEF significantly
inhibited HCMV infection-induced apoptosis and proliferation, playing an important role in the treatment of
patients infected by HCMV. In this study we explored the potential usefulness of LEF for cytomegalovirus infection
and found it to be a cost-effective new treatment for cytomegalovirus infection that deserves further study.
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Leflunomide (LEF) is an immunosuppressive drug used
clinically for the treatment of transplantation patients.
Interestingly, besides its immunosuppressive activities,
LEF can interfere with the replication of many viruses.
Human cytomegalovirus (HCMV) belongs to the β sub-
family of the herpes virus, and is the most common
pathogen of utero and postnatal infection, which can
cause stillbirth, fetal malformation, miscarriage, devel-
opmental retardation and abnormal liver function.
HCMV is the major pathogen of congenital malforma-
tions, growth retardation of the nervous system, hearing
and visual impairment, blood system diseases, infant
hepatitis and other serious diseases. HCMV infections
are also common causes for people who have low im-
mune function, such as organ transplant or AIDS
patients. HCMV can replicate in the human embryonic
lung fibroblasts. The mechanism of apoptosis inducted
by HCMV infection is not clear. Another study showed
that HCMV infection can cause clinical disease and
apoptosis, which are closely related to each other [1]. As
cell physiological death, apoptosis play an important
role in reducing aging and maintaining the balance of
the body, but when the cell undergoes abnormal apop-
tosis it can cause a variety of diseases. In recent years,
the study of HCMV and cell apoptosis has made great
progress. The relationship between HCMV and apop-
tosis is more complexHCMV can inhibit cell apoptosis
or promote apoptosis in the infection body [2]. The
study found that the early stages of HCMV infection
manifested as inhibition of apoptosis, which provided
sufficient time for HCMV in cell proliferation [3]. With
extension of the time of infection, however, the inhib-
ition of apoptosis was changed by the promotion of
apoptosis, which can cause loss of cell function and a
number of pathological and clinical diseases. The higher
the dose of HCMV infection, the sooner the cell
mediated apoptosis [4]. LEF is a novel immunosuppres-
sant, formation of the active metabolite A771726 play-
ing a role in the body. Treatment with LEF A771726




The cells were obtained from Zhongshan University
(Ethical approval was given by the medical ethics com-
mittee of Sun Yat-sen University with the following
reference number: SYXK20070081), and were main-
tained in 1640 medium, supplemented with 10% fetal
calf serum and 1 × 105 U/l penicillin, and treated with
the LEFHCMV and ganciclovir (GCV). The experiment
was divided into four groups: the control group, the
HCMV group, the GCV +HCMV group, as well as theLEF + HCMV group. The control group included 0.02%
DMSO RPMI 1640, the HCMV group included HCMV,
the GCV + HCMV intervention group included GCV
and HCMV, and the LEF + HCMV intervention group
included LEF and HCMV. Cells were then incubated at
37°C with a humidified atmosphere of 5% CO2 in air.
The above experimentwas performed three times.Assessment of inhibitory rate
MTT was used to assessthe cell inhibitory rate. Cell
suspensions were placed in triplicate in 96-well culture
plates at 10,000 cells/100 μl per well. Cells were incu-
bated for 96 hours at 37°C and 100 μl MTT solution
was added to each well. Cells were then incubated at
37°C for a further 4 hours. The plates were read on an
automatic plate reader at a wavelength of 570 nm and
the background absorbance measured at 690 nm was
subtracted.
Inhibitory rate %ð Þ ¼ experimental group=control groupð Þ
100:
The above experiments were repeated three times.Assessment of apoptosis
Cells grown under growth-restrictive conditions were
plated at a density of 1 × 106/ml and allowed to attach
to tissue culture plates for 24 hours. Cells then were
incubated with medium that contained 10% fetal bovine
serum in the presence or absence of HCMV. LEF or
GCV was added to the medium after 1 hour. The
percentage of apoptotic cells was assessed, and cells
were harvested at 24 hours and 48 hours. Apoptosis was
measured by staining with fluorescein isothiocyanate–
Annexin V and propidium iodide ((Sigma-Aldrich,
Guangzou, Guangdong, China)). We then added 500 μl cell
suspension liquid to 5 μl fluorescein isothiocyanate–
Annexin V and 5 μl propidium iodide, avoiding light at 4°C
for 10 minutes. Absorbance was recorded at an excita-
tion wavelength of 448 nm, collecting 10,000 cellsfor
each sample specimen. The cell apoptosis rate was then
measured using the relevant software. The experiment
was repeated three times.Statistical analysis
Statistical significance of differences in measured vari-
ables between controls and treated groups was deter-
mined by paired t test using SPSS for Windows V.13.0
(SPSS, Chicago, IL, USA). ≤0.05 was considered statis-
tically significant.
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Inhibitory effect of leflunomide on human embryo lung
cells infected with HCMV
The results of this study showed that cell proliferation
was significantly inhibited by HCMV at 24 hours and 48
hours (see Table 1). With increasing HCMV concentra-
tion, the value-added inhibition of cells was significantly
decreased compared with the control group andwas
statistically significant (P <0.01). GCV can increase
proliferation of cells infected with HCMV, statistically
significantly (P <0.05) compared with the control group.
Meanwhile, with LEF treatment the cell proliferation
was significantly improved at 24 hoursand 48 hours,
with statistical significance (P <0.05). Results are shown
in Figures 1, 2 and 3.
Effect of leflunomide on the proliferation of human
embryonic lung cells
The final concentration of LEF was divided into three
separate groups 40 g/ml, 20 g/ml, and 5 g/ml. The effect
of human fetal lung cell proliferation at the different
doses of LEF was still significant (P <0.05).
Apoptosis detection
The apoptosis rate of human embryonic lung fibroblasts
infected with HCMV increased significantly at 24 hours,
48 hours and 72 hours, and as time goes on the apop-
tosis rate increases; compared with the control group it
was statistically significant (P < 0.01). The apoptosis rate
of the HCMV infection group decreased by adding LEF,
and was statistically significant (P <0.05). See Figures 4
and 5.
Discussion
Cytomegalovirus (CMV) is one of the most important
infections in the immunosuppressed patient. CMV
disease often remains a life-threatening complication. In
addition, studies have suggested a role for this virus as a
contributing factor in allograft rejection. In the absence
of any preventative therapy, CMV infection occurs in
approximately 30 to 75% of transplant recipients, with
an incidence of CMV disease between 8 and 80%. CMV
infection may cause indirect effects, including acute
and chronic re-infection, increased risk of cardiacTable 1 Inhibitory rate of leflunomide on human embryo lun
Group n 24 hours 48
Control 6 0.523 ± 0.045 0.81
LEF1 6 0.43 ± 0.062* 0.57
LEF2 6 0.568 ± 0.045* 0.84
LEF3 6 0.654 ± 0.032* 0.93
LEF, leflunomide. compared with the control; *p <0.05, *P <0.05.complications, diabetes, and even death. Several drugs
have been developed and approved for CMV treatment.
Apoptosis is programmed cell death, and is a multicel-
lular animal life activity through gene regulation. Apop-
tosis mechanisms and the relationship of apoptosis with
disease has become a hot topic in the field of biomedical
research. Early stages of HCMV infection can block the
apoptosis pathway to ensureviral protein synthesis, as-
sembly and replication, resulting in persistent infection.
HCMV infection increases the host cell apoptotic loss
of cell function, leading to clinical symptoms. HCMV
occurs mainly through the endogenous pathway to pro-
mote apoptosis [5], and p53 is an apoptosis regulatory
factorthat plays an important role.
LEF is an inhibitor of protein kinase activity, and is an
immunosuppressive drug used in rheumatoid arthritis
and organ transplantation. Many reports have described
the benefit of LEF for CMV infection and clinical use
[6,7]. LEFis currently under discussion for use as an
antiviral substance in the clinic, because of its inhibitory
effects on several viruses. LEF is cheaper and is easily
given orally compared with other antivirals. LEF works
via a novel mechanism and also has immunosuppressive
properties. This study also found that LEF was effective
in CMV infection. Given these considerations we
believe that LEF is an exciting new drug for CMV infec-
tion. An American study showed that 88% of kidney
transplant recipients suffered CMV infection [8]. Many
studies have shownthat the meaningful value of LEF lies
in its organ transplantation, bone marrow transplant-
ation and hematopoietic stem cell transplant recipients
with CMV infection [9]. In addition, animal experiment-
sof CMV confirmed that after treatment usingLEF the
intracellular levels were significantly decreased by 75 to
99% [10]. LEF treated active rheumatoid arthritis
patients with the HLA-DRB1 gene [11]. Recent studies
have shown that LEF can reduce CMV infection of
transplant recipients [12]. In addition, rheumatoid arth-
ritis, systemic lupus erythematosus, glomerular diseases,
skin diseases and other therapeutic areas also achieved
good results. It is encouraging that LEF in the treatment
of HCMV infection has also been a widespread concern
[13]. The first report stated that LEF has anti-HCMV
effects in renal transplant recipients. Recent clinicalg cells
hours Inhibitory rate (%)
24 hours 48 hours
3 ± 0.078
2 ± 0.061* 39.7 47.1
± 0.028* 21.4 30.8
2 ± 0.031* 8.3 12.5
Figure 1 Cell changes in cell morphology at 24 hours and 48 hours. (A) Control group (normal human embryonic lung fibroblast at
24 hours, microscope × 200). (B) Control group (normal human embryonic lung fibroblast at 48 hours, microscope × 400). (C) Human
cytomegalovirus (HCMV) group (human embryonic lung fibroblast infected with HCMV at 24 hours, microscope × 200). (D) HCMV group (human
embryonic lung fibroblast infected with HCMV at 48 hours, microscope × 400). (E) Ganciclovir (GCV) + HCMV group (GCVadded to the human
embryonic lung fibroblast infected with HCMV at 24 hours, microscope × 200). (F) GCV + HCMV group (GCV added to the human embryonic lung
fibroblast infected with HCMV at 48 hours, microscope × 400). (G) Leflunomide (LEF) + HCMV group (LEF added to human embryonic lung
fibroblast infected with HCMV at 24 hours, microscope × 200). (H) LEF + HCMV group (LEF added to the human embryonic lung fibroblast
infected with HCMV at 48 hours, microscope × 400).
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Figure 2 Leflunomide inhibition rate of cytomegalovirus infection in each group at 24 hours.
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effect on HCMV infection disease after renal transplant-
ation and reduces viremia, promotes the involvement of
organ function recovery, and increases sensitivity to
GCV in mice with HCMV infection [14-16]. LEF has a
significant effect on refractory retinitis after allogeneic
bone marrow transplantation in drug-resistant HCMV
infection [17-19]. Some studies have shown that the
LEF has a good effect on the stubborn resistance of
HCMV infection [20,21].
In this study, we observed that cell proliferation was sig-
nificantly inhibited by HCMV at 24 hours and 48 hours.
With increasing HCMV concentrations, the value-added
inhibition of cells was significantly decreased compared
with the control group, and was statistically significant
(P <0.01). Meanwhile, treatment with LEF significantly
improved cell proliferation at 24 hours and 48 hours,
with statistical significance (P <0.05). The effect of
human fetal lung cell proliferation at the different dosesFigure 3 Leflunomide inhibition rate of cytomegalovirus infection in
(LEF) inhibition rate of cytomegalovirus (CMV) infection has obvious effects
infection group was statistically significant (P <0.05).of LEF was still significant (P <0.05). In addition, the
apoptosis rate of human embryonic lung fibroblasts
infected with HCMV increased significantly at 24 hours,
48 hours and 72 hours, and as time goes on the apop-
tosis rate is increased; compared with the control group
it was statistically significant (P <0.01). The apoptosis
rate of the HCMV infection group decreased by adding
LEF, and was statistically significant (P <0.05). This find-
ing confirmed that LEF is an effective new treatment for
CMV infection.
Conclusions
The search for newer more cost-effective treatments
for infectious diseases remains a challenge. In this
study, we believe that LEF is an exciting new drug for
CMV infection. The future is likely to be first-line or
second-line drug treatment for organ transplantation.
AIDS immunocompromised patients infected with
HCMV also rely on more clinical evidence, but oureach group at 48 hours. In this study, we found that the leflunomide
at 24 hours and 48 hours. Compared with the control group, the CMV
Figure 4 Apoptosis in each group at 24 hours, 48 hours and 72 hours.
Leflunomide anti-apoptotic rate of cells infected with cytomegalovirus
Apoptosis 
rat
Figure 5 Apoptosis rate of cells at 24 hours, 48 hours and 72 hours. At 24 hours, 48 hours and 72 hours, leflunomide (LEF) has a significant
anti-human cytomegalovirus (anti-HCMV) infection. Compared with the control group, the apoptotic effect of cytomegalovirus (CMV)
infectionwas significant (P <0.05).
Qi et al. European Journal of Medical Research 2013, 18:3 Page 6 of 7
http://www.eurjmedres.com/content/18/1/3
Qi et al. European Journal of Medical Research 2013, 18:3 Page 7 of 7
http://www.eurjmedres.com/content/18/1/3study showed that LEF significantly inhibited HCMV
infection-induced apoptosis and proliferation, playing
a important role in the treatment of patients infected
by HCMV. In this study, we explored the potential use-
fulness of LEF for CMV infection and found that it to
be a cost-effective new treatment for CMV infection
that deserves further study.
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